BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Arcera Life Sciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Arcera Life Sciences's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07619833-312@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Envlo (Enavogliflozin): Phase 3 readout est. (NCT07619833)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 3\, Type 2 Diabetes.\nStudy: To 
 Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16
 001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monothera
 py in Patients With Type 2 Diabetes Mellitus\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enav
 ogliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07619833
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
